In vitro inhibition of SARS virus replication by human interferons
Identifieur interne : 005B21 ( Main/Curation ); précédent : 005B20; suivant : 005B22In vitro inhibition of SARS virus replication by human interferons
Auteurs : Helena Dahl [Suède] ; Annika Linde [Suède] ; Örjan Strannegard [Suède]Source :
- Scandinavian journal of infectious diseases [ 0036-5548 ] ; 2004.
Descripteurs français
- KwdFr :
- MESH :
- pharmacologie : Antiviraux, Interféron alpha, Interféron bêta.
- physiologie : Virus du SRAS.
- Pascal (Inist)
- Wicri :
- topic : Homme.
English descriptors
- KwdEn :
- Animals, Antiviral Agents (pharmacology), Chlorocebus aethiops, Human, Humans, In vitro, Interferon, Interferon alpha-2, Interferon-alpha (pharmacology), Interferon-beta (pharmacology), Recombinant Proteins, Replication, SARS Virus (drug effects), SARS Virus (physiology), Severe acute respiratory syndrome, Vero Cells, Virus, Virus Replication (drug effects).
- MESH :
- chemical , pharmacology : Antiviral Agents, Interferon-alpha, Interferon-beta.
- drug effects : SARS Virus, Virus Replication.
- physiology : SARS Virus.
- Animals, Chlorocebus aethiops, Humans, Interferon alpha-2, Recombinant Proteins, Vero Cells.
Abstract
Four different types of human interferon, interferon-β (IFN-β), recombinant IFN-α2a and IFN-a2b and natural IFN-α were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-β was found to be the most highly active antiviral agent, followed by natural IFN-a, whereas the 2 recombinant IFN-a2 species were poorly active in the system used. These results suggest that IFN-β as well as natural IFN-a may be used for the treatment of SARS.
Links toward previous steps (curation, corpus...)
- to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000743
- to stream PascalFrancis, to step Curation: Pour aller vers cette notice dans l'étape Curation :000247
- to stream PascalFrancis, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000831
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005F82
- to stream PubMed, to step Corpus: Pour aller vers cette notice dans l'étape Curation :002845
- to stream PubMed, to step Curation: Pour aller vers cette notice dans l'étape Curation :002845
- to stream PubMed, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :002C47
- to stream Ncbi, to step Merge: Pour aller vers cette notice dans l'étape Curation :000E35
- to stream Ncbi, to step Curation: Pour aller vers cette notice dans l'étape Curation :000E35
- to stream Ncbi, to step Checkpoint: Pour aller vers cette notice dans l'étape Curation :000E35
- to stream Main, to step Merge: Pour aller vers cette notice dans l'étape Curation :005701
Links to Exploration step
Pascal:05-0060697Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro inhibition of SARS virus replication by human interferons</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strannegard, Orjan" sort="Strannegard, Orjan" uniqKey="Strannegard O" first="Örjan" last="Strannegard">Örjan Strannegard</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Virology, Göteborg University</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Göteborg</settlement>
<region nuts="1">Götaland</region>
<region nuts="1">Suède occidentale</region>
</placeName>
<orgName type="university">Université de Göteborg</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0060697</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0060697 INIST</idno>
<idno type="RBID">Pascal:05-0060697</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000743</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000247</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000831</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000831</idno>
<idno type="wicri:doubleKey">0036-5548:2004:Dahl H:in:vitro:inhibition</idno>
<idno type="wicri:Area/Main/Merge">005F82</idno>
<idno type="wicri:source">PubMed</idno>
<idno type="RBID">pubmed:15764169</idno>
<idno type="wicri:Area/PubMed/Corpus">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002845</idno>
<idno type="wicri:Area/PubMed/Curation">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002845</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C47</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C47</idno>
<idno type="wicri:Area/Ncbi/Merge">000E35</idno>
<idno type="wicri:Area/Ncbi/Curation">000E35</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E35</idno>
<idno type="wicri:doubleKey">0036-5548:2004:Dahl H:in:vitro:inhibition</idno>
<idno type="wicri:Area/Main/Merge">005701</idno>
<idno type="wicri:Area/Main/Curation">005B21</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro inhibition of SARS virus replication by human interferons</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strannegard, Orjan" sort="Strannegard, Orjan" uniqKey="Strannegard O" first="Örjan" last="Strannegard">Örjan Strannegard</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Virology, Göteborg University</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Göteborg</settlement>
<region nuts="1">Götaland</region>
<region nuts="1">Suède occidentale</region>
</placeName>
<orgName type="university">Université de Göteborg</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Human</term>
<term>Humans</term>
<term>In vitro</term>
<term>Interferon</term>
<term>Interferon alpha-2</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-beta (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>Replication</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Severe acute respiratory syndrome</term>
<term>Vero Cells</term>
<term>Virus</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron bêta (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Recombinant Proteins</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Protéines recombinantes</term>
<term>Réplication virale</term>
<term>Syndrome respiratoire aigu sévère</term>
<term>Interféron</term>
<term>In vitro</term>
<term>Réplication</term>
<term>Homme</term>
<term>Virus</term>
<term>Virus du SRAS</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Four different types of human interferon, interferon-β (IFN-β), recombinant IFN-α2a and IFN-a2b and natural IFN-α were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-β was found to be the most highly active antiviral agent, followed by natural IFN-a, whereas the 2 recombinant IFN-a2 species were poorly active in the system used. These results suggest that IFN-β as well as natural IFN-a may be used for the treatment of SARS.</div>
</front>
</TEI>
<double idat="0036-5548:2004:Dahl H:in:vitro:inhibition"><INIST><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">In vitro inhibition of SARS virus replication by human interferons</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strannegard, Orjan" sort="Strannegard, Orjan" uniqKey="Strannegard O" first="Örjan" last="Strannegard">Örjan Strannegard</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Virology, Göteborg University</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Göteborg</settlement>
<region nuts="1">Götaland</region>
<region nuts="1">Suède occidentale</region>
</placeName>
<orgName type="university">Université de Göteborg</orgName>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">05-0060697</idno>
<date when="2004">2004</date>
<idno type="stanalyst">PASCAL 05-0060697 INIST</idno>
<idno type="RBID">Pascal:05-0060697</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000743</idno>
<idno type="wicri:Area/PascalFrancis/Curation">000247</idno>
<idno type="wicri:Area/PascalFrancis/Checkpoint">000831</idno>
<idno type="wicri:explorRef" wicri:stream="PascalFrancis" wicri:step="Checkpoint">000831</idno>
<idno type="wicri:doubleKey">0036-5548:2004:Dahl H:in:vitro:inhibition</idno>
<idno type="wicri:Area/Main/Merge">005F82</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">In vitro inhibition of SARS virus replication by human interferons</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
<affiliation wicri:level="3"><inist:fA14 i1="01"><s1>Swedish Institute for Infectious Disease Control</s1>
<s2>Stockholm</s2>
<s3>SWE</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Strannegard, Orjan" sort="Strannegard, Orjan" uniqKey="Strannegard O" first="Örjan" last="Strannegard">Örjan Strannegard</name>
<affiliation wicri:level="4"><inist:fA14 i1="02"><s1>Department of Clinical Virology, Göteborg University</s1>
<s2>Göteborg</s2>
<s3>SWE</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Suède</country>
<placeName><settlement type="city">Göteborg</settlement>
<region nuts="1">Götaland</region>
<region nuts="1">Suède occidentale</region>
</placeName>
<orgName type="university">Université de Göteborg</orgName>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
<imprint><date when="2004">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Scandinavian journal of infectious diseases</title>
<title level="j" type="abbreviated">Scand. j. infect. dis.</title>
<idno type="ISSN">0036-5548</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Human</term>
<term>In vitro</term>
<term>Interferon</term>
<term>Replication</term>
<term>Severe acute respiratory syndrome</term>
<term>Virus</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Syndrome respiratoire aigu sévère</term>
<term>Interféron</term>
<term>In vitro</term>
<term>Réplication</term>
<term>Homme</term>
<term>Virus</term>
</keywords>
<keywords scheme="Wicri" type="topic" xml:lang="fr"><term>Homme</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Four different types of human interferon, interferon-β (IFN-β), recombinant IFN-α2a and IFN-a2b and natural IFN-α were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-β was found to be the most highly active antiviral agent, followed by natural IFN-a, whereas the 2 recombinant IFN-a2 species were poorly active in the system used. These results suggest that IFN-β as well as natural IFN-a may be used for the treatment of SARS.</div>
</front>
</TEI>
</INIST>
<PubMed><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author><name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">PubMed</idno>
<date when="2004">2004</date>
<idno type="RBID">pubmed:15764169</idno>
<idno type="pmid">15764169</idno>
<idno type="doi">10.1080/00365540410021144</idno>
<idno type="wicri:Area/PubMed/Corpus">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">002845</idno>
<idno type="wicri:Area/PubMed/Curation">002845</idno>
<idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Curation">002845</idno>
<idno type="wicri:Area/PubMed/Checkpoint">002C47</idno>
<idno type="wicri:explorRef" wicri:stream="Checkpoint" wicri:step="PubMed">002C47</idno>
<idno type="wicri:Area/Ncbi/Merge">000E35</idno>
<idno type="wicri:Area/Ncbi/Curation">000E35</idno>
<idno type="wicri:Area/Ncbi/Checkpoint">000E35</idno>
<idno type="wicri:doubleKey">0036-5548:2004:Dahl H:in:vitro:inhibition</idno>
<idno type="wicri:Area/Main/Merge">005701</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en">In vitro inhibition of SARS virus replication by human interferons.</title>
<author><name sortKey="Dahl, Helena" sort="Dahl, Helena" uniqKey="Dahl H" first="Helena" last="Dahl">Helena Dahl</name>
<affiliation wicri:level="3"><nlm:affiliation>Swedish Institute for Infectious Disease Control, Stockholm, Sweden. Helena.Dahl@smi.ki.se</nlm:affiliation>
<country xml:lang="fr">Suède</country>
<wicri:regionArea>Swedish Institute for Infectious Disease Control, Stockholm</wicri:regionArea>
<placeName><settlement type="city">Stockholm</settlement>
<region nuts="2">Svealand</region>
</placeName>
</affiliation>
</author>
<author><name sortKey="Linde, Annika" sort="Linde, Annika" uniqKey="Linde A" first="Annika" last="Linde">Annika Linde</name>
</author>
<author><name sortKey="Stranneg Rd, Orjan" sort="Stranneg Rd, Orjan" uniqKey="Stranneg Rd O" first="Orjan" last="Stranneg Rd">Orjan Stranneg Rd</name>
</author>
</analytic>
<series><title level="j">Scandinavian journal of infectious diseases</title>
<idno type="ISSN">0036-5548</idno>
<imprint><date when="2004" type="published">2004</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Animals</term>
<term>Antiviral Agents (pharmacology)</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Interferon-alpha (pharmacology)</term>
<term>Interferon-beta (pharmacology)</term>
<term>Recombinant Proteins</term>
<term>SARS Virus (drug effects)</term>
<term>SARS Virus (physiology)</term>
<term>Vero Cells</term>
<term>Virus Replication (drug effects)</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr"><term>Animaux</term>
<term>Antiviraux (pharmacologie)</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Interféron alpha (pharmacologie)</term>
<term>Interféron bêta (pharmacologie)</term>
<term>Protéines recombinantes</term>
<term>Réplication virale ()</term>
<term>Virus du SRAS ()</term>
<term>Virus du SRAS (physiologie)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en"><term>Antiviral Agents</term>
<term>Interferon-alpha</term>
<term>Interferon-beta</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en"><term>SARS Virus</term>
<term>Virus Replication</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr"><term>Antiviraux</term>
<term>Interféron alpha</term>
<term>Interféron bêta</term>
</keywords>
<keywords scheme="MESH" qualifier="physiologie" xml:lang="fr"><term>Virus du SRAS</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en"><term>SARS Virus</term>
</keywords>
<keywords scheme="MESH" xml:lang="en"><term>Animals</term>
<term>Chlorocebus aethiops</term>
<term>Humans</term>
<term>Interferon alpha-2</term>
<term>Recombinant Proteins</term>
<term>Vero Cells</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr"><term>Animaux</term>
<term>Cellules Vero</term>
<term>Humains</term>
<term>Protéines recombinantes</term>
<term>Réplication virale</term>
<term>Virus du SRAS</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Four different types of human interferon, interferon-beta (IFN-beta), recombinant IFN-alpha2a and IFN-alpha2b and natural IFN-alpha were tested for antiviral activity against SARS-coronavirus. The experiments were performed using in vitro cultivated monkey Vero E6 cells. IFN-beta was found to be the most highly active antiviral agent, followed by natural IFN-alpha, whereas the 2 recombinant IFN-alpha2 species were poorly active in the system used. These results suggest that IFN-beta as well as natural IFN-alpha may be used for the treatment of SARS.</div>
</front>
</TEI>
</PubMed>
</double>
</record>
Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/SrasV1/Data/Main/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 005B21 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Curation/biblio.hfd -nk 005B21 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien |wiki= Sante |area= SrasV1 |flux= Main |étape= Curation |type= RBID |clé= Pascal:05-0060697 |texte= In vitro inhibition of SARS virus replication by human interferons }}
This area was generated with Dilib version V0.6.33. |